When Maria Rodriguez, a 54-year-old school counselor from Philadelphia, received her tisagenlecleucel infusion in 2014, she was out of options—her follicular lymphoma had returned after four rounds of chemotherapy and a stem cell transplant. Ten years later, she remains in remission, one of the growing number of patients whose lives have been quietly rewritten by CAR T-cell therapy. At the Abramson Cancer Center at the University of Pennsylvania, long-term follow-up data from a landmark Phase II trial reveals that 36% of patients with large B-cell lymphoma and 48% with follicular lymphoma remained relapse-free a decade after a single infusion of the pioneering treatment developed by Dr. Carl June. For a group of patients once facing terminal diagnoses, these numbers are more than statistics—they’re milestones of survival.
This therapy, the first CAR T-cell treatment approved by the FDA, reprograms a patient’s own immune cells to hunt down and destroy cancer. The study tracked 38 patients, including 24 with large B-cell lymphoma and 14 with follicular lymphoma, all of whom had relapsed or resisted prior treatments. Remarkably, no relapses occurred after 5.4 years, with most cancer recurrences happening within the first 12 months post-infusion. This pattern strengthens the idea that long-term responders may, in fact, be cured—a word used sparingly in oncology. Dr. Stephen J. Schuster, director of Penn’s Lymphoma Program, put it plainly: 'As oncologists, we use the word 'cure' with great care, but I am increasingly confident that CAR T-cell therapy has the potential to cure a meaningful number of patients with B-cell lymphomas.'
Beyond survival, the study offers reassuring safety insights. While nine patients developed a second primary cancer over the decade—including three with acute myeloid leukemia, all linked to prior chemotherapy exposure—no cases of CAR T cell-related lymphoma were detected. More than half of long-term responders regained normal B-cell function, a sign of immune recovery, without lymphoma returning. The persistence of CAR T cells in the blood over the first two years emerged as a stronger predictor of lasting remission than initial cell expansion, a finding that could shape future dosing and monitoring strategies.
The implications are profound. Because many patients entered the trial after enduring multiple toxic therapies, researchers like lead author Dr. Marco Ruella believe moving CAR T-cell treatment earlier in the care pathway—before immune systems are weakened—could unlock even greater success. 'Moving CAR T-cell therapy into earlier lines of treatment—before patients experience the cumulative effects of chemotherapy—may be key to extending its curative potential,' Ruella said. At Penn and beyond, new trials are exploring whether pre-infusion lymphodepleting chemotherapy can be reduced or eliminated, streamlining the process for future patients. As science inches closer to turning once-fatal cancers into manageable or even curable conditions, stories like Maria’s are no longer outliers—they’re harbingers of a new era in cancer care.